missing translation for 'onlineSavingsMsg'
Learn More

Tocris Bioscience™ BIRB 796

High affinity and selective p38 kinase inhibitor

167.00€ - 610.00€

Specifications

Chemical Name or Material N-[3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N′-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea
CAS 285983-48-4
Synonym Doramapimod
Target p38 Inhibitors
Molecular Formula C31H37N5O3
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
18757996
View Documents
Tocris Bioscience™
5989/10
10 mg
167.00€
10mg
Estimated Shipment: 03-01-2025
to see stock.
Add to basket
 
18737196
View Documents
Tocris Bioscience™
5989/50
50 mg
610.00€
50mg
Estimated Shipment: 29-01-2025
to see stock.
Add to basket
 
Description

Description

High affinity and selective p38 kinase inhibitor (Kd = 50-100 pM). Exhibits no significant inhibition on a panel of related kinases. Inhibits LPS-induced TNFα production in human PBMCs and whole blood (IC50 values are 21 and 960 nM, respectively). Also inhibits JNK2α2 and c-Raf-1 (IC50 values are 98 nM and 1.4 μM, respectively). Cell permeable.
Specifications

Specifications

N-[3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N′-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea
Doramapimod
C31H37N5O3
0.98
285983-48-4
p38 Inhibitors
527.66
Videos
Safety and Handling

Safety and Handling

Recommended Storage : Store at -20°C

SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.